Join us at booth 1553
The annual cancer research meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; this meeting showcases cutting-edge cancer science and medicine.
Meet the Oxford Nanopore team at Booth 1553 in the exhibit hall, and will host an Exhibitor Spotlight Theater Monday, April 28th, 2025. See session details below.
Exhibitor Spotlight Theater
Unlock Transformative Cancer Insights: The power of ultra-rich nanopore sequencing
Join us to explore how nanopore sequencing enables the integration of multiomic molecular information to deepen our understanding of cancer biology and pave the way for more precise diagnostics in the future.
In this session, you will learn how Dr. Debarshi Mustafi, professor of ophthalmology at the UW School of Medicine is using nanopore sequencing to determine parent of origin in Retinoblastoma, which is associated with different disease trajectories.
Later, hear how Dr. Gabriel Griffin, Principal Investigator at the Dana-Farber Cancer Institute and Harvard Medical School, is leveraging direct DNA methylation sequencing to create a rapid epigenomic classifier for Acute Myeloid Leukemia. This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit.
The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research® (AACR).”
Date: Monday, April 28th
Time: 12:30 pm - 1:30 pm CT
Location: Spotlight Theater C
Agenda
12:30 – 1:30 pm CT | Talk title | Speaker |
|---|---|---|
12:30 pm - 12:50 pm | Oxford Nanopore introduction and overview | Claire Attwooll, Oxford Nanopore Technologies |
12:50 pm - 1:10 pm | Prognostic importance of direct assignment of parent-of-origin via long-read genome and epigenome sequencing in retinoblastoma | Debarshi Mustafi, University of Washington |
1:10 pm - 1:30 pm | Rapid epigenomic classification of acute leukemia | Gabriel E. Griffin, Dana-Farber Cancer Institute |
Spotlight Theater speakers
)
Oxford Nanopore introduction
Claire Attwooll, Senior Director, Clinical Solutions, Oxford Nanopore Technologies
Claire Attwooll, Ph.D., is an accomplished Sales and Marketing leader with a strong background in On...
)
Prognostic importance of direct assignment of parent-of-origin via long-read genome and epigenome sequencing in retinoblastoma
Debarshi Mustafi, Principal Investigator, University of Washington
Debarshi grew up in Chicago and earned his bachelor’s degree with Honors in Chemistry from the Unive...
)
Rapid epigenomic classification of acute leukemia
Gabriel Griffin, Assistant Professor, Dana-Farber Cancer Institute
Dr. Griffin is Assistant Professor of Pathology at Harvard Medical School, Principal Investigator in...
Register
On-booth activities
Sunday, April 27th | Monday, April 28th | Tuesday, April 29th | Wednesday, April 30th |
|---|---|---|---|
10:15 am — Characterising genomic and epigenomic variants in tumour-normal research samples with Oxford Nanopore EPI2ME analysis workflow Sergey Aganezov, Oxford Nanopore Technologies | 10:15 am — Characterising genomic and epigenomic variants in tumour-normal research samples with Oxford Nanopore EPI2ME analysis workflow Sergey Aganezov, Oxford Nanopore Technologies | 11:30 am — Flow cell loading/initiating a sequencing run Maddy Hartley, Oxford Nanopore Technologies | |
11:30 am — Flow cell loading/initiating a sequencing run Maddy Hartley, Oxford Nanopore Technologies | 12:30 pm — Uncover novel cancer biology with scRNAseq and long-read sequencing Patrick Murphy, Oxford Nanopore Technologies | ||
3:00 pm — Flow cell loading/initiating a sequencing run Maddy Hartley, Oxford Nanopore Technologies | 3:00 pm — Comprehensive multi-omic data from a single assay with the Oxford Nanopore Hereditary Cancer Panel Rob King, Oxford Nanopore Technologies | 3:00 pm — Beyond bisulfite conversion: Rapid, real-time tumor methylation profiling via direct DNA sequencing Claire Attwooll, Oxford Nanopore Technologies |